As news broke that Carson Wentz is returning to the Minnesota Vikings for 2026, insiders have been suggesting he would have remained as the starter over J.J. McCarthy last year if not for the shoulder ...

As more drugmakers tally up their CEO compensation for 2025, yet another Big Pharma chief has collected above the $30 million threshold. Johnson & Johnson CEO Joaquin Duato has been awarded nearly $32 ...

Do not use on systems you do not own or have explicit permission to test. This tool is for authorised testing in controlled environments only. Unauthorised access to computer systems is illegal. The ...

Microsoft releases SQL Server 2025 CU2 with bug fixes and performance improvements. Update addresses backup, disaster recovery, replication, storage and resource governor issues. Regular cumulative ...

The Minnesota Vikings and their quarterback discussion are not going anywhere anytime soon. First-year starter J.J. McCarthy had a rollercoaster 2025 season, highlighted by poor play and injuries, ...

Devart, a leading developer of database management software, is offering dbForge 2025.3, the latest update to its unified ecosystem of professional database tools—delivering expanded connectivity, ...

Add Futurism (opens in a new tab) Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. The headlines of 2025 ...

Johnson & Johnson had another strong quarter, driven by revenue growth of two important cancer drugs, but it also reported lower-than-expected net profit. J&J reported steady revenue performance in ...

Johnson & Johnson (JNJ), the earnings bellwether for the healthcare sector, reported better-than-expected revenue for Q4 2025 on Tuesday thanks to its Pharma and MedTech divisions. However, the shares ...

Johnson & Johnson now expects to bring in $100 billion in revenue in 2026. (Photo by Mario Tama/Getty Images) Johnson & Johnson had another strong quarter, driven by revenue growth of two important ...

Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while standing fast on its talc lawsuit and tariffs. Johnson & Johnson is eyeing ...